Thus, incretin-based glucose-lowering medications, in particular GLP-1 receptor agonists (GLP-1RAs), have proven to be effective and are currently used in T2DM treatment [13,14,15,16,17,18]. This evidence concerns the gene GCG and type 2 diabetes mellitus.